|
(Health-NewsWire.Net, May 26, 2015 ) Dallas, TX -- The report “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and special features on late-stage and discontinued projects.
Familial hypercholesterolemia is a disorder that is passed down through families. It causes low density lipoprotein cholesterol levels to be very high. The condition begins at birth and can cause heart attacks at an early age. The major symptoms and signs of familial hypercholesterolemia are: LDL cholesterol, A strong family history of high levels of total and LDL cholesterol, Elevated and therapy-resistant levels of LDL in either or both parents, Xanthomas, Xanthelasmas, Corneal arcus.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Pipeline Review, H1 2015 report include: Aegerion Pharmaceuticals, Inc., Amgen Inc., Cerenis Therapeutics Holding SA, CymaBay Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., ReGenX Biosciences, LLC, Sanofi.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=375210 . (This is a premium report priced at US$2000 for a single user License.)
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
• The report provides a snapshot of the global therapeutic landscape of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
RnR Market Research
Ritesh Tiwari
+18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
